Literature DB >> 27077080

Data on skeletal muscle apoptosis, autophagy, and morphology in mice treated with doxorubicin.

Troy L Campbell1, Joe Quadrilatero1.   

Abstract

Skeletal muscle apoptosis and autophagy are catabolic processes that contribute to muscle atrophy during aging, disease, and following muscle injury. In this article, we present data on skeletal muscle apoptosis, autophagy, and morphology in C57BL/6 mice following doxorubicin administration. More specifically, time-course data on caspase-3, caspase-8, caspase-9, calpain, and cathepsin activity are presented, along with data on ATG7, p62, LC3-I, and LC3-II protein expression. Data on skeletal muscle reactive oxygen species (ROS) production, muscle morphology, as well as body and muscle weights are also presented.

Entities:  

Keywords:  Apoptosis; Autophagy; Doxorubicin; Skeletal muscle

Year:  2016        PMID: 27077080      PMCID: PMC4816877          DOI: 10.1016/j.dib.2016.03.009

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specification Table Value of the data Provides a simultaneous assessment of skeletal muscle apoptosis, autophagy, and morphology in response to systemic doxorubicin administration. Provides time-course data on skeletal muscle morphology and degradative processes following doxorubicin administration. Valuable for researchers interested in the relationship between apoptosis and autophagy in skeletal muscle. Help other researchers determine the utility of doxorubicin as a myotoxic agent.

Data

Here we present data regarding the ability of systemic doxorubicin administration to induce skeletal muscle atrophy and morphological changes. Given that apoptosis and autophagy can impact muscle morphology and wasting [1], [2] we also provide data on apoptotic and autophagic signaling in several muscles following doxorubicin administration.

Body and muscle weights following doxorubicin administration

There was a trend (p=0.07) towards a significant decrease in body weight after doxorubicin administration (Fig. 1A). There were no statistically significant differences in soleus, plantaris, or gastrocnemius weights with doxorubicin. Further, there were no significant differences in muscle weights when normalized to body weight for both the soleus (Fig. 1B) or plantaris (Fig. 1C) following doxorubicin administration. However, post hoc analysis revealed a significant (p<0.05) difference in gastrocnemius weight when normalized to body weight at day 1 compared to day 9 (Fig. 1D).
Fig. 1

Body weight (A), as well as soleus (B), plantaris (C), and gastrocnemius (D) muscle weights normalized to body weight (BW) prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration (n=3). *p<0.05, significant difference compared to day 9.

Apoptotic enzyme activity and reactive oxygen species (ROS) generation following doxorubicin treatment

There were no statistically significant differences in caspase-3 (Fig. 2A), caspase-8 (Fig. 2B), caspase-9 (Fig. 2C), or calpain (Fig. 2D) activity, nor ROS production (Fig. 2E) in mixed gastrocnemius between any of the measured time points (Day 0, 1, 3, 5, 7, and 9) following doxorubicin administration.
Fig. 2

Caspase-3 (A), caspase-8 (B), caspase-9 (C), and calpain (D) activity, as well as ROS generation (E) data from mixed gastrocnemius prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration (n=3).

Autophagic protein expression and cathepsin activity after doxorubicin administration

There were no differences in ATG7 (Fig. 3A and C) or p62 (Fig. 3A and D) protein between any of the measured time points in the soleus following doxorubicin administration. Post hoc analysis revealed a significant (p<0.05) increase in LC3-I protein in soleus on day 3 post-doxorubicin injection compared to day 1 (Fig. 3A and E). There was no statistically significant difference in LC3-II protein (Fig. 3A and F), nor the LC3-II/LC3-I protein ratio (Fig. 3A and G) in the soleus at any time point following doxorubicin administration. There were no significant differences in ATG7 protein (Fig. 3B and C) at any time point after doxorubicin administration in the plantaris muscle. However, p62 protein (Fig. 3B and D) was significantly (p<0.05) higher on day 3 compared to day 0, 1, 5, and 9. There were no significant differences in LC3-I protein (Fig. 3B and E), LC3-II protein (Fig. 3B and F), or the LC3-II/LC3-I protein ratio (Fig. 3B and G) in the plantaris at any time point following doxorubicin administration. Finally, there were no statistically significant differences in cathepsin activity between time points in mixed gastrocnemius following doxorubicin administration (Fig. 3H).
Fig. 3

Representative immunoblots from soleus (A) and plantaris (B) of ATG7, p62, LC3-I, and LC3-II protein expression prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration. Quantitative analysis of ATG7 (C), p62 (D), LC3-I (E), and LC3-II (F) protein, as well as the LC3-II/LC3-I protein ratio (G) in soleus and plantaris before and after doxorubicin treatment (n=3). Quantitative analysis of cathepsin activity (H) from mixed gastrocnemius prior to and following doxorubicin injection (n=3). *p<0.05, significant difference compared to day 0, 1, 5, and 9. #p<0.05, significant difference compared to day 1.

Qualitative analysis of muscle morphology after doxorubicin exposure

Visual inspection of soleus and plantaris cross-sections stained with hematoxylin & eosin (H & E) showed no obvious signs of muscle damage or changes in muscle morphology at any time point after doxorubicin administration (Fig. 4). Additionally, there were no apparent increases in the presence of centralized nuclei after doxorubicin administration.
Fig. 4

Representative H & E stained muscle cross-sections from soleus and plantaris muscle prior to (day 0) and following (day 1, 3, 5, 7, 9) doxorubicin administration. Scale bar=100 µm.

Experimental design, materials and methods

Experimental design

Male C57BL/6 mice between the ages of 13–17 weeks were sacrificed by cervical dislocation prior to (i.e. day 0) and 1, 3, 5, 7, or 9 days (n=3 for each time point) following a single intraperitoneal injection of doxorubicin at a concentration of 20 mg/kg body weight. This dose has previously been shown to induce atrophy, damage, oxidative stress, and apoptotic and autophagic signaling in skeletal muscle at 24 h or 48 h following administration [3], [4], [5], [6].

Muscle extraction and sample preparation

After sacrifice, the soleus, plantaris, and gastrocnemius (mixed) were extracted from both hindlimbs. A sample of the entire circumference from the middle portion of one soleus and one plantaris was mounted in Optimal Cutting Temperature (OCT) compound and frozen in liquid nitrogen-cooled isopentane. The remaining soleus and plantaris, as well as the mixed gastrocnemius, were individually frozen in liquid nitrogen and stored at −80 °C. Soleus and plantaris muscle samples used for immunoblotting were homogenized in ice-cold lysis buffer (20 mM HEPES, 10 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 20% glycerol and 0.1% Triton X-100; pH 7.4) containing protease inhibitors (Complete Cocktail; Roche Diagnostics). Mixed gastrocnemius muscle samples used for caspase, calpain, and cathepsin activity assays were homogenized in lysis buffer but without protease inhibitors. Homogenates were then centrifuged for 10 min at 1000g at 4 °C and supernatants collected and stored at −80 °C. Mixed gastrocnemius samples for ROS assays were homogenized in ice-cold buffer (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT; pH 7.4) containing protease inhibitors (Complete Cocktail; Roche Diagnostics). Total protein concentrations were determined by the BCA protein assay.

Proteolytic enzyme activity

Caspase-3, -8, and -9 activity in mixed gastrocnemius homogenates were assessed using the substrates Ac-DEVD-AMC (Enzo Life Sciences), Ac-IETD-AMC (Sigma-Aldrich), and Ac-LEHD-AMC (Enzo Life Sciences), respectively, as previously performed [7]. Calpain activity was measured in mixed gastrocnemius homogenates using Suc-LLVY-AMC (Enzo Life Sciences) either with or without the calpain inhibitor Z-LL-CHO (Enzo Life Sciences). Calpain activity was calculated as the difference between the average fluorescence of wells with and without the inhibitor [7]. Cathepsin activity was determined in mixed gastrocnemius homogenates using z-FR-AFC (Enzo Life Sciences) as previously described [8]. Fluorescence for all enzymes was determined using a SPECTRAmax Gemini XS microplate spectrofluorometer (Molecular Devices), then normalized to total protein content, and expressed as arbitrary units per milligram of protein.

Reactive oxygen species generation

Reactive oxygen species (ROS) generation was assessed in mixed gastrocnemius using dichlorofluorescein-diacetate (DCFH-DA) (Life Technologies) [9]. Fluorescence was determined using a SPECTRAmax Gemini XS microplate spectrofluorometer (Molecular Devices). Fluorescence was normalized to total protein content and presented as arbitrary units per milligram of protein.

Immunoblotting analyses

Immunoblotting was performed using soleus and plantaris muscle samples as previously described [10]. Briefly, equal amounts of protein were loaded into 12% SDS-PAGE gels, separated by electrophoresis, and transferred onto PVDF membranes (BioRad). Blocked membranes were incubated in primary antibody against ATG7 (Cell Signaling Technology), LC3B (Cell Signaling Technology), and p62 (Progen Biotechnik) overnight at 4 °C, washed, and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology) for 1 h at room temperature. Protein bands were imaged using Clarity Western ECL Substrate (BioRad) and the ChemiGenius 2 Bio-Imaging System (Syngene). Membranes were also stained with Ponceau S (Sigma-Aldrich) to verify equal protein loading and quality of protein transfer.

Histochemical analyses

Soleus and plantaris muscle cross-sections mounted on microscope slides were first stained with hematoxylin for 30 s, after which excess hematoxylin was quickly removed, and slides washed in distilled water. Cross-sections were then stained with eosin for 90 s, after which excess eosin was quickly removed. Slides were then treated with graded ethanol incubations, a xylene clearing step, and finally coverslips mounted with permount.

Statistical analyses

All quantitative data was analyzed using 1-way ANOVAs and Tukey׳s post hoc tests, with p<0.05 being considered statistically significant.
Subject areaBiology
More specific subject areaSkeletal muscle, apoptosis, autophagy
Type of dataImages, graphs, figures
How data was acquiredMicroscopy, spectrofluorometry, immunoblotting
Data formatAnalyzed
Experimental factorsC57BL/6 mice received a single intraperitoneal injection of doxorubicin and were sacrificed at given time points.
Experimental featuresC57BL/6 mice were sacrificed prior to (i.e. day 0) and 1, 3, 5, 7, and 9 days after a single intraperitoneal injection of doxorubicin. Different skeletal muscles were isolated and weighed, and samples prepared for microscopy, spectrofluorometric assays, and immunoblotting.
Data source locationUniversity of Waterloo, Waterloo, Ontario, Canada
Data accessibilityAll data are provided with this article
  10 in total

1.  High-fat feeding does not induce an autophagic or apoptotic phenotype in female rat skeletal muscle.

Authors:  Troy L Campbell; Andrew S Mitchell; Elliott M McMillan; Darin Bloemberg; Dmytro Pavlov; Isabelle Messa; John G Mielke; Joe Quadrilatero
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-30

2.  Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.

Authors:  Kisuk Min; Oh-Sung Kwon; Ashley J Smuder; Michael P Wiggs; Kurt J Sollanek; Demetra D Christou; Jeung-Ki Yoo; Moon-Hyon Hwang; Hazel H Szeto; Andreas N Kavazis; Scott K Powers
Journal:  J Physiol       Date:  2015-02-23       Impact factor: 5.182

Review 3.  Autophagy in skeletal muscle.

Authors:  Marco Sandri
Journal:  FEBS Lett       Date:  2010-02-02       Impact factor: 4.124

4.  Autophagy is altered in skeletal and cardiac muscle of spontaneously hypertensive rats.

Authors:  D Bloemberg; E McDonald; D Dulay; J Quadrilatero
Journal:  Acta Physiol (Oxf)       Date:  2013-11-05       Impact factor: 6.311

5.  Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle.

Authors:  Ashley J Smuder; Andreas N Kavazis; Kisuk Min; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2011-02-10

6.  Differential apoptosis-related protein expression, mitochondrial properties, proteolytic enzyme activity, and DNA fragmentation between skeletal muscles.

Authors:  Elliott M McMillan; Joe Quadrilatero
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-09       Impact factor: 3.619

7.  Functional, morphological, and apoptotic alterations in skeletal muscle of ARC deficient mice.

Authors:  Andrew S Mitchell; Ian C Smith; Daniel Gamu; Stefan Donath; A Russell Tupling; Joe Quadrilatero
Journal:  Apoptosis       Date:  2015-03       Impact factor: 4.677

8.  Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle.

Authors:  Ashley J Smuder; Andreas N Kavazis; Kisuk Min; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2011-07-21

9.  Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle.

Authors:  Andreas N Kavazis; Ashley J Smuder; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2014-06-19

10.  Molecular and cellular mechanisms of skeletal muscle atrophy: an update.

Authors:  Alessandro Fanzani; Viviane M Conraads; Fabio Penna; Wim Martinet
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-06-07       Impact factor: 12.910

  10 in total
  1 in total

1.  Protection against Doxorubicin-Induced Cardiac Dysfunction Is Not Maintained Following Prolonged Autophagy Inhibition.

Authors:  Ryan N Montalvo; Vivian Doerr; Oh Sung Kwon; Erin E Talbert; Jeung-Ki Yoo; Moon-Hyon Hwang; Branden L Nguyen; Demetra D Christou; Andreas N Kavazis; Ashley J Smuder
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.